Critical Contrast: ProMetic Life Sciences (OTCMKTS:PFSCF) versus Ampio Pharmaceuticals (NYSE:AMPE)

Volatility & Risk

ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 5.96, suggesting that its stock price is 496% more volatile than the S&P 500.

Earnings and Valuation

This table compares ProMetic Life Sciences and Ampio Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02

Ampio Pharmaceuticals has lower revenue, but higher earnings than ProMetic Life Sciences.

Insider & Institutional Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 3.3% of Ampio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares ProMetic Life Sciences and Ampio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
Ampio Pharmaceuticals	N/A	N/A	N/A

Summary

Ampio Pharmaceuticals beats ProMetic Life Sciences on 7 of the 8 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.